Group 1 - The core point of the article is the appointment of Zhou Yunshu, a former senior executive at Heng Rui Medicine, as the president of Xiansheng Pharmaceutical Group, although the company later clarified that this information is not entirely accurate and no formal internal appointment has been made yet [1][3] - Zhou Yunshu has a long history with Heng Rui Medicine, having joined the company in 1995 and serving in various leadership roles, including general manager and chairman [4] - Zhou resigned from his positions at Heng Rui Medicine in July 2021 due to health reasons, and he was later involved in an insider trading case, resulting in a fine from the China Securities Regulatory Commission [4] Group 2 - Xiansheng Pharmaceutical is a well-established domestic pharmaceutical company focusing on areas such as neuroscience, oncology, and autoimmune diseases, and is also undergoing a transformation towards innovation [4] - In the first half of 2025, Xiansheng Pharmaceutical reported revenues of 3.585 billion yuan and a net profit attributable to shareholders of 604 million yuan, representing year-on-year growth of 15.14% and 32.20%, respectively [4] - The company's innovative drug business generated revenue of 2.776 billion yuan, a year-on-year increase of 26%, accounting for 77.4% of total revenue [4] - In 2025, Xiansheng Pharmaceutical announced three business development transactions, including licensing agreements for several drug candidates with AbbVie and other companies [5]